RightFit Trial Directory

Lung Cancer clinical trials in Cincinnati, OH

27 recruiting lung cancer studies with a site in Cincinnati, OH.

All trials in Cincinnati, OH · All Lung Cancer trials

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Akron, OH · Alliance, OH · Beavercreek, OH · +1147 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Cincinnati, OH · +53 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Canton, OH · Cincinnati, OH · +50 more sites

RecruitingPhase 3NCT06712355

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor: BioNTech SE

Akron, OH · Canton, OH · Cincinnati, OH · +33 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Cincinnati, OH · +19 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Avon, OH · Cincinnati, OH · +238 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Canton, OH · Cincinnati, OH · +223 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Centerville, OH · Cincinnati, OH · Columbus, OH · +84 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Akron, OH · Cincinnati, OH · Cleveland, OH · +35 more sites

RecruitingPhase 3NCT07361510

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Sponsor: Bristol-Myers Squibb

Cincinnati, OH · +40 more sites

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Cincinnati, OH · Columbus, OH · Maumee, OH · +60 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Canton, OH · Centerville, OH · Cincinnati, OH · +53 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Cincinnati, OH · Cleveland, OH · Columbus, OH · +94 more sites

RecruitingPhase not listedNCT05059444

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Sponsor: Guardant Health, Inc.

Cincinnati, OH · Cleveland, OH · Toledo, OH · +30 more sites

RecruitingPhase 1 / Phase 2NCT07491497

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

Sponsor: TRIANA Biomedicines, Inc.

Cincinnati, OH · Maumee, OH · +12 more sites

RecruitingPhase 1NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Sponsor: Eli Lilly and Company

Cincinnati, OH · Cleveland, OH · +23 more sites

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Canton, OH · Cincinnati, OH · +28 more sites

RecruitingPhase 1NCT05433142

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Xencor, Inc.

Cincinnati, OH · Columbus, OH · +18 more sites

RecruitingPhase 1 / Phase 2NCT05361174

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Sponsor: Iovance Biotherapeutics, Inc.

Cincinnati, OH · +10 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Belpre, OH · Canton, OH · +451 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Alliance, OH · Athens, OH · Beachwood, OH · +1226 more sites

RecruitingPhase 1 / Phase 2NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Sponsor: Revolution Medicines, Inc.

Cincinnati, OH · Maumee, OH · +19 more sites

RecruitingPhase 3NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Sponsor: University of Texas Southwestern Medical Center

Cincinnati, OH · Cleveland, OH · +37 more sites

RecruitingPhase 1 / Phase 2NCT05785741

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Sponsor: DualityBio Inc.

Cincinnati, OH · +14 more sites

RecruitingPhase not listedNCT05236114

GEMINI-NSCLC: NSCLC Biomarker Study

Sponsor: Tempus AI

Canton, OH · Cincinnati, OH · Columbus, OH · +55 more sites

RecruitingPhase 1 / Phase 2NCT05914116

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Sponsor: DualityBio Inc.

Canton, OH · Cincinnati, OH · Dayton, OH · +25 more sites

RecruitingPhase 2NCT07207395

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

Sponsor: The Christ Hospital

Cincinnati, OH

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.